Replies to post #22664 on RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Benedik's purchase was likely related to Cortex's 30,000 share minimum ownership requirement for management. His shares now equal exactly 30,000.

Neuro, BTW, any thoughts on Cypress' newly approved fibromyalgia drug Savella? Looks like it may have more cardio side effects than current treatments like Cymbalta, but some analysts are predicting it will take a big share of the market. Looks like Cypress will get a 15% royalty from Forest on US sales.

[gfp927z]

Neuro, Any thoughts on the delay of Schering's Saphris/Asenapine approval? Even if approved, do you think it will be competitive in the marketplace?

From Cortex's perspective, I guess the FDA's rejection of Schering/Organon's Suggamedex last year was potentially a key development, since its approval could have put Schering in the mix as a potential RD partner.

Speaking of Schering, they'll soon have their Org-26576 ADHD Phase 2 results (the 'final data collection date' is Jan '09, and 'study completion date' is March '09). They should already have the Org-26576 Depression Phase 1/2 data.